New UK biotech company PepGen has raised $45m in Series A funding and has unveiled Duchenne muscular dystrophy (DMD) as the first target for its next-generation oligonucleotide platform.
Spun out two years ago from Oxford University with funding from Oxford Science Innovation (OSI), PepGen’s financing has been led...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
